Year: 2015
Session type: Oral, Symposia
Ira Mellman1
1Genentech, South San Francisco, USA
Paul Boutros1
1Ontario Institute for Cancer Research, Toronto, Canada
Johnathan Whetstine1
1Harvard Medical School & Massachusetts General Hospital Cancer Center, Boston, USA
Adrian Hayday1
1King’s College London & The francis Crick Institute, London, UK
Jos Jonkers1
1Netherlands Cancer Institute, Amsterdam, The Netherlands
Joe O’Sullivan1,2
1Queen’s University Belfast, Belfast, Northern Ireland, UK,2Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK
Katherine Vallis1
1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK
Peter Sasieni1
1Queen Mary University of London, London, UK
Laurence Zitvogel1
1Institut Gustave Roussy and INSERM, Villejuif, France
Wolf Reik1
1Babraham Institute, Cambridge, UK,2Centre for Trophoblast Research, University of Cambridge, Cambridge, UK,3Wellcome Trust Sanger Institute, Cambridge, UK
Mark Bunnage1
1Pfizer, Cambridge, MA, USA
Ultan McDermott1
1Wellcome Trust Sanger Institute, Hinxton, UK
Wim Oyen1,2
1The Institute of Cancer Research, London, UK,2The Royal Marsden NHS Foundation Trust, London, UK
David Kent1,2
1Wellcome Trust/ MRC Cambridge Stem Cell Institute, Cambridge, UK,2Department of Haematology University of Cambridge, Cambridge, UK
Rebecca Fitzgerald1
1Univeristy of Cambridge, Cambridge, UK
Marc Tischkowitz1
1University of Cambridge, Cambridge, UK
Peter Anderson1
1Newcastle University, Newcastle, UK
Nicholas Luscombe1
1The Francis Crick Institute, London, UK
Paolo Boffetta1
1Icahn School of Medicine at Mount Sinai, New York NY, USA
Jo Morris1
1University of Birmingham, West Midlands, UK
Martin Wiseman1,2
1WCRF International, London, UK,2University of Southampton, Southampton, UK
Jessica Downs1
1Genome Damage and Stability Centre, Falmer, Brighton, UK
Sohrab Shah1,2
1BC Cancer Agency Research Centre, Vancouver, BC, Canada,2University of British Columbia, Vancouver, BC, Canada
Year: 2011
Session type: Symposia